Lucía Simón-Carrasco

Lucía Simón-Carrasco

Auto-generated profile, based on publicly available information

Lucía Simón-Carrasco

Tumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MDMatthias Drosten
Matthias Drosten
ESEleanor Y. M. Sum
Eleanor Y. M. Sum
CLCarmen G. Lechuga
Carmen G. Lechuga
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
HJHarrys Kishore Charles Jacob
Harrys Kishore Charles Jacob
MBMariano Barbacid
Mariano Barbacid
The Ras family of small GTPases constitutes a central node in the transmission of mitogenic stimuli to the cell cycle machinery. The ultimate receptor of these mitogenic signals is the retinoblastoma (Rb) family of pocket proteins, whose inactivation is a required step to license cell proliferation. However, little is known regarding the molecular events that connect Ras signaling with the cell cycle. Here, we provide genetic evidence to illustrate that the p53/p21 Cdk-interacting protein 1 (Cip1)/Rb axis is an essential component of the Ras signaling pathway. Indeed, knockdown of p53, p21Cip1, or Rb restores proliferative properties in cells arrested by ablation of the three Ras loci, H-, N- and K-Ras. Ras signaling selectively inactivates p53-mediated induction of p21Cip1 expression by inhibiting acetylation of specific lysine residues in the p53 DNA binding domain. Proliferation of cells lacking both Ras proteins and p53 can be prevented by reexpression of the human p53 ortholog, provided that it retains an active DNA binding domain and an intact lysine residue at position 164. These results unveil a previously unidentified role for p53 in preventing cell proliferation under unfavorable mitogenic conditions. Moreover, we provide evidence that cells lacking Ras and p53 proteins owe their proliferative properties to the unexpected retroactivation of the Raf/Mek/Erk cascade by a Ras-independent mechanism.

22 February 2019 in Genome Research
Verified
Journal Article
Open access
PDF file
Kasper RasmussenKasper Rasmussen
Kasper Rasmussen
IBIvan Berest
Ivan Berest
SKSandra Keβler
Sandra Keβler
KNKoutarou Nishimura
Koutarou Nishimura
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
KHKristian Helin
Kristian Helin
The epigenetic regulator TET2 is frequently mutated in hematological diseases. Mutations have been shown to arise in hematopoietic stem cells early in disease development and lead to altered DNA methylation landscapes and an increased risk of hematopoietic malignancy. Here, we show by genome-wide mapping of TET2 binding sites in different cell types that TET2 localizes to regions of open chromatin and cell-type–specific enhancers. We find that deletion of Tet2 in native hematopoiesis as well as fully transformed acute myeloid leukemia (AML) results in changes in transcription factor (TF) activity within these regions, and we provide evidence that loss of TET2 leads to attenuation of chromatin binding of members of the basic helix–loop–helix (bHLH) TF family. Together, these findings demonstrate that TET2 activity shapes the local chromatin environment at enhancers to facilitate TF binding and provides an example of how epigenetic dysregulation can affect gene expression patterns and drive disease development.

9 March 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MFMarta Forés
Marta Forés
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
LALeiore Ajuria
Leiore Ajuria
NSNúria Samper
Núria Samper
SGSergio González-Crespo
Sergio González-Crespo
GJGerardo Jiménez
Gerardo Jiménez
HMG-box proteins, including Sox/SRY (Sox) and TCF/LEF1 (TCF) family members, bind DNA via their HMG-box. This binding, however, is relatively weak and both Sox and TCF factors employ distinct mechanisms for enhancing their affinity and specificity for DNA. Here we report that Capicua (CIC), an HMG-box transcriptional repressor involved in Ras/MAPK signaling and cancer progression, employs an additional distinct mode of DNA binding that enables selective recognition of its targets. We find that, contrary to previous assumptions, the HMG-box of CIC does not bind DNA alone but instead requires a distant motif (referred to as C1) present at the C-terminus of all CIC proteins. The HMG-box and C1 domains are both necessary for binding specific TGAATGAA-like sites, do not function via dimerization, and are active in the absence of cofactors, suggesting that they form a bipartite structure for sequence-specific binding to DNA. We demonstrate that this binding mechanism operates throughout Drosophila development and in human cells, ensuring specific regulation of multiple CIC targets. It thus appears that HMG-box proteins generally depend on auxiliary DNA binding mechanisms for regulating their appropriate genomic targets, but that each sub-family has evolved unique strategies for this purpose. Finally, the key role of C1 in DNA binding also explains the fact that this domain is a hotspot for inactivating mutations in oligodendroglioma and other tumors, while being preserved in oncogenic CIC-DUX4 fusion chimeras associated to Ewing-like sarcomas. Transcription factors bind specific sites in the genome via discrete protein domains that recognize their target DNA sequences. One such domain is the HMG-box, which is found in many chromatin and transcriptional regulators across species. Two salient groups of HMG-box proteins are the Sox/SRY and TCF/LEF1 factors, which are involved in multiple developmental and signaling processes. Extensive genetic and molecular studies have shown, however, that both groups of proteins do not simply bind DNA through their HMG-box, but rely either on additional protein domains or associated factors for targeting their correct sites in the genome. In this work, we have focused on another HMG-box protein, Capicua (CIC), which has recently emerged as an important mediator of Ras/MAPK signaling in both Drosophila and mammals. We find that the HMG-box of CIC does not bind DNA alone and instead requires a separate conserved motif (C1) present in all CIC proteins. The C1 domain is restricted to CIC proteins and exhibits several properties that distinguish it from Sox and TCF domains involved in DNA binding. Thus, CIC proteins represent a separate sub-family of HMG-box factors that have evolved an independent mechanism for enhancing the DNA-binding capabilities of their HMG-box. Notably, our results also explain distinct patterns of human CIC mutations that either inactivate CIC tumor suppressor function or produce oncogenic fusions between CIC and the DUX4 activator factor.

15 July 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
OGOsvaldo Graña
Osvaldo Graña
MSMarina Salmón
Marina Salmón
HJHarrys Kishore Charles Jacob
Harrys Kishore Charles Jacob
AGAlejandro Gutierrez
Alejandro Gutierrez
MBMariano Barbacid
Mariano Barbacid
CIC (also known as Capicua) is a transcriptional repressor negatively regulated by RAS/MAPK signaling. Whereas the functions of Cic have been well characterized in Drosophila, little is known about its role in mammals. CIC is inactivated in a variety of human tumors and has been implicated recently in the promotion of lung metastases. Here, we describe a mouse model in which we inactivated Cic by selectively disabling its DNA-binding activity, a mutation that causes derepression of its target genes. Germline Cic inactivation causes perinatal lethality due to lung differentiation defects. However, its systemic inactivation in adult mice induces T-cell acute lymphoblastic lymphoma (T-ALL), a tumor type known to carry CIC mutations, albeit with low incidence. Cic inactivation in mice induces T-ALL by a mechanism involving derepression of its well-known target, Etv4. Importantly, human T-ALL also relies on ETV4 expression for maintaining its oncogenic phenotype. Moreover, Cic inactivation renders T-ALL insensitive to MEK inhibitors in both mouse and human cell lines. Finally, we show that Ras-induced mouse T-ALL as well as human T-ALL carrying mutations in the RAS/MAPK pathway display a genetic signature indicative of Cic inactivation. These observations illustrate that CIC inactivation plays a key role in this human malignancy.

19 March 2018 in Cell Cycle
Verified
Journal Article
Closed access
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
GJGerardo Jiménez
Gerardo Jiménez
MBMariano Barbacid
Mariano Barbacid
MDMatthias Drosten
Matthias Drosten
The transcriptional repressor Capicua (CIC) has emerged as an important rheostat of cell growth regulated by RAS/MAPK signaling. Cic was originally discovered in Drosophila, where it was shown to be inactivated by MAPK signaling downstream of the RTKs Torso and EGFR, which results in signal-dependent responses that are required for normal cell fate specification, proliferation and survival of developing and adult tissues. CIC is highly conserved in mammals, where it is also negatively regulated by MAPK signaling. Here, we review the roles of CIC during mammalian development, tissue homeostasis, tumor formation and therapy resistance. Available data indicate that CIC is involved in multiple biological processes, including lung development, liver homeostasis, autoimmunity and neurobehavioral processes. Moreover, CIC has been shown to be involved in tumor development as a tumor suppressor, both in human as well as in mouse models. Finally, several lines of evidence implicate CIC as a determinant of sensitivity to EGFR and MAPK pathway inhibitors, suggesting that CIC may play a broader role in human cancer than originally anticipated.

31 January 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
MDMatthias Drosten
Matthias Drosten
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
IHIsabel Hernández-Porras
Isabel Hernández-Porras
CLCarmen G. Lechuga
Carmen G. Lechuga
MBMaría T. Blasco
María T. Blasco
MBMariano Barbacid
Mariano Barbacid
Genetic studies in mice have provided evidence that H-Ras and K-Ras proteins are bioequivalent. However, human tumors display marked differences in the association of RAS oncogenes with tumor type. Thus, to further assess the bioequivalence of oncogenic H-Ras and K-Ras, we replaced the coding region of the murine K-Ras locus with H-RasG12V oncogene sequences. Germline expression of H-RasG12V or K-RasG12V from the K-Ras locus resulted in embryonic lethality. However, expression of these genes in adult mice led to different tumor phenotypes. Whereas H-RasG12V elicited papillomas and hematopoietic tumors, K-RasG12V induced lung tumors and gastric lesions. Pulmonary expression of H-RasG12V created a senescence-like state caused by excessive MAPK signaling. Likewise, H-RasG12V but not K-RasG12V induced senescence in mouse embryonic fibroblasts. Label-free quantitative analysis revealed that minor differences in H-RasG12V expression levels led to drastically different biological outputs, suggesting that subtle differences in MAPK signaling confer nonequivalent functions that influence tumor spectra induced by RAS oncoproteins. Cancer Res; 77(3); 707–18. ©2016 AACR.